Genentech has long been a leader in understanding and advancing the fields of cancer biology, cancer immunology and oncology drug discovery.
Our scientists understand that cancer is a complex problem involving factors intrinsic to the tumor that drive its formation, together with tumor-extrinsic mechanisms — notably the vasculature and the immune system — that enable tumor survival. We understand the importance of attacking both types of mechanisms in a coordinated fashion.
Building off of our early successes in the clinic, we have built a dedicated effort to understand how a patient’s immune response can be activated to achieve durable benefit and potentially cure, extending our understanding of cancer immunology to pursue new and innovative targets. At the same time, we retain a strong commitment to investigating the cancer cell itself, finding new opportunities in targeting in oncogenic and tumor suppressive pathways, as well as in next-generation antibody-drug conjugates. All our efforts are linked by exploring therapeutic combinations and by a commitment to pursuing personalized medicines.
Genentech scientists discovered a cancer paradox. How can blocking the same pathway have the opposite effect in two different types of cells?
Investigational next-generation selective estrogen receptor degraders (SERDs) are a class of small molecules that may exert a big effect on a key driver of breast cancer.